Formulation: A solid
Formal Name: (S)-2-((5S,8S,11S,14S,17S,23S,26S)-14-((1H-imidazol-5-yl)methyl)-17-benzyl-11-((R)-1-hydroxyethyl)-5-(hydroxymethyl)-23,26-diisobutyl-8-methyl-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazanonacosanamido)-6-amino-N-((5S,8S,11S,14S,17S,20S)-1,24-diamino-14-(4-aminobutyl)-11-((S)-sec-butyl)-5-carbamoyl-17-isopropyl-8-methyl-7,10,13,16,19-pentaoxo-6,9,12,15,18-pentaazatetracosan-20-yl)hexanamide, trifluoroacetate salt
Purity: ≥98%
Formula Markup: C81H139N23O19 • XCF3COOH
Formula Weight: 1739,1
Shelf life (days): 1460
Notes: BRC4wt is an acetylated peptide derived from the BRC4 repeat in human BRCA2 (1521-1536) and an inhibitor of the protein-protein interaction between BRCA2 and RAD51.{66463} When coupled to the cationic cell-penetrating peptide (Arg)9 (Item No. 36714), BRC4wt shortens DNA replication tract lengths and reduces homologous repair frequency of DNA damage induced by the DNA topoisomerase I inhibitor camptothecin (Item No. 11694) in vitro, as well as potentiates cell death induced by the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Item No. 10621) in HeLa human cervical cancer and U2OS human osteosarcoma cells but not in non-cancerous hTERT RPE-1, MRC-5, or MCF-10A cells.
English
Deutsch
